Insider Transactions in Q4 2020 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 02
2020
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-1.26%
|
$2,880,000
$96.82 P/Share
|
|
Oct 30
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,903
-29.16%
|
$990,300
$100.12 P/Share
|
|
Oct 30
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,903
+22.62%
|
$534,762
$54.5 P/Share
|
|
Oct 28
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
97
-0.4%
|
$9,700
$100.0 P/Share
|
|
Oct 28
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
97
+0.4%
|
$5,238
$54.5 P/Share
|
|
Oct 14
2020
|
Shalini Sharp EVP, Finance |
SELL
Open market or private sale
|
Direct |
375
-0.38%
|
$32,625
$87.99 P/Share
|
|
Oct 14
2020
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
146
-0.88%
|
$12,702
$87.98 P/Share
|
|
Oct 14
2020
|
Dennis Karl Huang |
SELL
Open market or private sale
|
Direct |
262
-0.75%
|
$23,056
$88.0 P/Share
|
|
Oct 14
2020
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
262
-0.56%
|
$23,056
$88.0 P/Share
|
|
Oct 14
2020
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
220
-0.93%
|
$19,360
$88.0 P/Share
|
|
Oct 14
2020
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
262
-0.26%
|
$22,794
$87.98 P/Share
|
|
Oct 14
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
325
-1.34%
|
$28,600
$88.0 P/Share
|
|
Oct 14
2020
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
262
-0.73%
|
$23,056
$88.0 P/Share
|
|
Oct 14
2020
|
Emil D Kakkis President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
852
-0.14%
|
$78,384
$92.69 P/Share
|
|
Oct 12
2020
|
Mardi Dier CFO & Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
Oct 12
2020
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
2,780
-5.63%
|
$261,320
$94.47 P/Share
|
|
Oct 08
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-29.16%
|
$950,000
$95.0 P/Share
|
|
Oct 08
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+22.58%
|
$540,000
$54.5 P/Share
|
|
Oct 06
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-29.16%
|
$900,000
$90.0 P/Share
|
|
Oct 06
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+22.58%
|
$480,000
$48.43 P/Share
|